Related Experiment Videos
Response of immunocompromised children with solid tumors to a conjugate vaccine for Haemophilus influenzae type b
J L Shenep1, S Feldman, F Gigliotti
1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105-2794.
Insights
Children undergoing chemotherapy for solid tumors showed a serum antibody response to the Haemophilus influenzae type b vaccine. Antibody responses were observed in 42% after the first dose and 45% after revaccination.
Area of Science:
- Pediatric Oncology
- Immunology
- Vaccinology
Background:
- Children with solid tumors undergoing chemotherapy are often immunocompromised.
- Assessing vaccine immunogenicity in this population is crucial for infection prevention.
Purpose of the Study:
- To evaluate the serum antibody response to a conjugated Haemophilus influenzae type b vaccine in nonvaccinated children receiving chemotherapy.
- To determine the immunogenicity of the vaccine after primary vaccination and revaccination.
Main Methods:
- Serum antibody levels were measured in children aged 1.5 to 5 years receiving chemotherapy.
- A conjugated polyribosylribitol phosphate-diphtheria toxoid vaccine was administered.
- Response was assessed after initial vaccination and a subsequent booster dose.
Main Results:
- Antibody responses were observed in 21 out of 50 (42%) children after the first vaccination.
- In children who received a second dose (revaccination), 10 out of 22 (45%) showed an antibody response.
Conclusions:
- The conjugated Haemophilus influenzae type b vaccine elicits a detectable antibody response in a subset of children undergoing chemotherapy for solid tumors.
- Further research may be needed to optimize vaccination strategies in this vulnerable population.
Abstract:
Serum antibody response to a conjugated Haemophilus influenzae type b polyribosylribitol phosphate-diphtheria toxoid vaccine was assessed in nonvaccinated children aged 1 1/2 to 5 years receiving chemotherapy for solid tumors. Responses occurred in 21 (42%) of 50 children after first vaccination, and in 10 (45%) of 22 revaccinated children.